@LBleuBlancRouge Les listes de gauche vont souffrir de l'abstention. Leurs électeurs font leur Ramadan, ils dorment le matin, cuisinent l'apres midi et font l'iftar le soir.
@GabLattanzio@jo_delb Avez-vous visité un pays musulman en plein Ramadam ? La population du 93 ne va pas gâcher une journée de Ramadan dans un bureau de vote.
ADA Standards of Care 2026: The New Algorithm for Glucose-Lowering Therapy in Type 2 Diabetes
The ADA 2026 reinforces a priorities-first approach:
1️⃣ Reduce cardiovascular & kidney (CVKD) risk
2️⃣ Manage weight
3️⃣ Achieve glycemic goals
4️⃣ Address MASLD/MASH risk
All built on a foundation of healthy lifestyle + DSMES + addressing SDOH.
🔶 1. FIRST PRIORITY: Cardiovascular & Kidney Risk Reduction
A. ASCVD or Indicators of High CV Risk
Preferred: GLP-1 RA with proven CV benefit
Alternative / Add-on: SGLT2i with proven CV benefit
If HbA1c above target → combine GLP-1 RA + SGLT2i
B. Heart Failure (HFpEF or HFrEF)
Preferred: SGLT2 inhibitor
Add GLP-1 RA (proven benefit) if glycemia not controlled or if comorbid obesity
C. CKD (eGFR <60 OR ACR ≥30 mg/g)
Preferred: SGLT2i with primary evidence of CKD protection
If eGFR <45 → GLP-1 RA with proven renal benefit
If glycemia above goal → combine SGLT2i + GLP-1 RA
If more CVKD risk reduction is needed
➡️ Add agents with proven benefit, treat lipids/BP aggressively, and reassess every 3–6 months.
🔶 2. SECOND PRIORITY: Weight Management
ADA 2026 clearly states:
Weight reduction itself is a therapeutic target in T2DM.
Weight-loss efficacy of medications (ADA 2026)
Very High: Semaglutide, Tirzepatide
High: Dulaglutide (high dose), Liraglutide
Intermediate: GLP-1 RA (others), SGLT2i
Neutral: DPP-4 inhibitors
Use GLP-1 RA / dual GIP-GLP-1 RA early in patients with obesity or weight-related complications.
🔶 3. THIRD PRIORITY: Glycemic Control
Efficacy for glucose lowering (ADA 2026)
Very High: Semaglutide, Tirzepatide, insulin combination therapy
High: GLP-1 RA, SGLT2i, Metformin, TZD, Sulfonylureas
Intermediate: DPP-4 inhibitors
If HbA1c remains above target → Stepwise intensification without delay.
🔶 4. NEW FOCUS 2026: MASLD/MASH (Metabolic Liver Disease)
ADA now adds a dedicated pathway:
Drugs with proven / potential benefit
GLP-1 RA
Dual GIP–GLP-1 RA
Pioglitazone
GLP-1 RA + Pioglitazone combination
⚠️ Use insulin in decompensated cirrhosis only.
🔶 5. When Treatment Goals Are Not Reached
Reassess every 3–6 months
Evaluate:
Barriers to care
Hypoglycemia risk
Adherence
Affordability
SDOH (social determinants of health)
⭐ CME INDIA Take-Home Messages
1️⃣ ADA 2026 is no longer “HbA1c-first”—it is “Heart–Kidney–Weight–Glycemia” in that order.
2️⃣ GLP-1 RA & SGLT2i dominate all therapeutic pathways due to CVKD & weight benefits.
3️⃣ Obesity is treated as a biological disease—not a lifestyle failure.
4️⃣ MASLD/MASH enters mainstream diabetes management for the first time.
5️⃣ Reassessment every 3–6 months is mandatory—clinical inertia is unacceptable.
https://t.co/wRp6gaKDvK
@le20hfrancetele Il veut attirer les "scientifiques" en sociologie, en études de genre, en patriarcat, en racialisme, ... qui se gavent de subventions pour produire des délires wokes.
Les vrais scientifiques en médecine et en technologie resent aux USA vu les salaires minables en France.
@Mediavenir Si les mineurs isolés ont en moyenne un âge osseux de 30 ans, les enfants de la maternelle auraient en réalité un age osseux de 14 ans. Elle sait bien de quoi elle parle 😁.